 |
| (사진= 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion and Mirae Asset Group have become the largest shareholders of Iksuda Therapeutics, a British antibody drug junction (ADC) developer.
According to Celltrion on the 25th, it signed a contract with Mirae Asset Group to participate in Iksuda Series A funding in June 2021. Iksuda Series A funding led by both companies is worth a total of $47 million (about 53 billion won). Through this, Celltrion and New Growth Fund secured a total stake of 47.05% on a combined basis.
Iksuda is a company that develops next-generation ADC for the development of incurable cancer treatments. It has antibody engineering technology that helps greatly improve the treatment index important for targeted treatment and an ADC platform for next-generation action mechanisms, including linker-payload.
Celltrion believes that the ADC sector can create high added value and create synergy with existing antibody treatment products, so it has selected ADC as one of its new growth engines and is conducting investment and collaboration.
Alphabiz Reporter Paul Lee(hoondork@alphabiz.co.kr)
